Robert P. Liscouski was appointed Director of Quantum Cyber N.V. As of November 14, 2026, Quantum Cyber N.V. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 17, 2026 to October 16, 2026, naming 1 appointment (Form 8-K, March 11, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Quantum Cyber N.V? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-16
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-05-18
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-28
- · In / out: In · Person: Robert P. Liscouski · Role: Director · 8-K, 2026-03-11
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-02-17
Quantum Cyber N.V. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-17 to 2026-10-16. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Quantum Cyber N.V. files it.
Also on the record for Quantum Cyber N.V.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 10, 2026 | Stake report, Schedule 13G, by Alexander Gurevich | 9.8% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13D/A, by Lazar David E. | 94.3% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13D, by Lazar David E. | 97.4% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
| January 20, 2026 | Stake report, Schedule 13G/A, by Donahue Kevin Michael | 10.7% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G, by Donahue Kevin Michael | 10.7% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Quantum Cyber N.V. now and the warning signs.
Free to see. No signup.
Keep reading
More on Quantum Cyber N.V. and the records around it.
Quantum Cyber N.V. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), KALA BIO, Inc. (Jul 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Quantum Cyber N.V.
Get an email when Quantum Cyber N.V. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Quantum Cyber N.V.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Quantum Cyber N.V.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Quantum Cyber N.V. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | Reported | not named in the filing | 8-K, 2026-10-16 | ||
| 2026-05-18 | Reported | not named in the filing | 8-K, 2026-05-18 | ||
| 2026-04-28 | Reported | not named in the filing | 8-K, 2026-04-28 | ||
| 2026-03-11 | In | Director | 8-K, 2026-03-11 | ||
| 2026-02-17 | Reported | not named in the filing | 8-K, 2026-02-17 |
Who leads Quantum Cyber N.V., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Robert P. Liscouski, appointed (filed 2026-03-11).
New leaders reset buying decisions — get the Full Report on Quantum Cyber N.V.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Quantum Cyber N.V., with the record behind each one.
Find candidates like Director at Quantum Cyber N.V.Every change, in the filing's words
Reported
Appointment of Alberto C. Rosende Effective as of October 12, 2026, to fill the vacancy in the composition of the Board of Directors (the "Board") of Quantum Cyber N.V.
- (Ret.) Rosende's successor is duly elected and qualified, or his earlier death, resignation or removal.
- (Ret.) Rosende has also been appointed to each of the Audit Committee, the Compensation Committee, and the Nomination Committee of the Board.
- (Ret.) Rosende will receive the Company's standard compensation for non-employee directors, which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 1, 2026.
- (Ret.) Rosende (i) qualifies as an independent director under the listing standards of the Nasdaq Stock Market ("Nasdaq") and (ii) satisfies the financial literacy requirements for audit committee membership under the Nasdaq listing standards.
- (Ret.) Rosende, age 64, brings nearly four decades of senior U.S. Army command experience to the Board, including his final assignment as Commanding General of the 63rd Readiness Division, where he was responsible for a seven-state southwestern region of the United States, comprising California, Nevada, New Mexico, Arizona, Texas, Arkansas, and Oklahoma.
- In this role, he oversaw more than 120 Army Reserve facilities, equipment maintenance support, and human resources support to a force of more than 41,000 Soldiers.
- He is a combat veteran of both Afghanistan and Iraq and a recipient of the Army Distinguished Service Medal, the Legion of Merit, and the Bronze Star.
Reported
Mr. O'Rourke has not yet been appointed to serve on any committee of the Board.
- Appointment of Director Effective as of May 13, 2026, to fill vacancy in the composition of the Board of Directors (the "Board"), the Board of the Company appointed Peter O'Rourke to serve as a director until the annual general meeting of the Company to be held in 2027 or until Mr. O'Rourke's successor is duly elected and qualified, or his earlier death, resignation or removal.
- Mr. O'Rourke will receive the Company's standard compensation for non-employee directors, which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 25, 2026.
- Peter O'Rourke has served as a director of the Board since May 2026.
- Mr. O'Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector, from December 2018 to present.
- From November 2020-July 2022, Mr. O'Rourke was President and Director for Western Magnesium Corporation where he created the U.S. operations strategy and team during the technology pilot phase of the company, and led enterprise and defense business development, government affairs, and communications.
- From January 2017 to December 2018, Mr. O'Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs.
- From May 2015 to July 2016, Mr. O'Rourke served as a principal of Calibre Systems, Inc., a consulting firm.
Reported
Director Appointments On April 22, 2026, our shareholders approved at an Extraordinary General Meeting the appointment of David Natan and Avraham Ben-Tzvi to our board of directors, and Mr. Natan and Mr. Ben-Tzvi became directors of our company.
- A brief biography for each of Mr. Natan and Mr. Ben-Tzvi is set out below: David Natan currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, both domestically and internationally, since 2007.
- From 2010 to May 2020, Mr. Natan served as Chief Executive Officer of Forcefield Energy, Inc., a company focused on the solar industry and LED lighting products.
- From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of PharmaNet Development Group, Inc., a drug development services and clinical trials company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components.
- Before that, Mr. Natan served various roles in increasing responsibility with Deloitte & Touche LLP, a global accounting and consulting firm.
- Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical and nutritional supplement company, since February 2022.
Appointed: Robert P. Liscouski, Director
On March 11, 2026, Robert P. Liscouski was appointed to the board of directors (the " Board ") of Mainz Biomed N.V.
- Mr. Liscouski was appointed as a director having a term expiring at the Company's extraordinary general meeting, currently planned for April 2026, or until his successor has been duly elected and qualified or until his earlier resignation or removal.
Reported
of this Current Report on Form 8-K below), our board of directors (the "Board") appointed Mr. Lazar as a director immediately prior to the First Closing.
- Securities Purchase Agreement The Purchase Agreement contains customary representations, warranties, and covenants of, as well as indemnification rights, and other obligations of the parties.
- Following the Conversion Approval (as defined below), the Fist Closing Shares, upon full conversion, would represent approximately 55.4% of our issued and outstanding Ordinary Shares on a fully diluted basis, and the Second Closing Shares to be issued, upon full conversion, would represent approximately 90.2% of our issued and outstanding Ordinary Shares on a fully diluted basis as of the Final Closing, or collectively approximately 95.6% in the aggregate (based on the number of Ordinary Shares anticipated to be outstanding as of the Final Closing).
- Since the Ordinary Shares are currently listed on the Nasdaq Capital Market, we are required to comply with the continued listing rules of The Nasdaq Stock Market LLC (the "Listing Rules"), and among these requirements are Rules 5635(d) and Rule 5635(b) of the Listing Rules.
- Rule 5635(b) of the Listing Rules requires stockholder approval of a transaction involving the sale, issuance or potential issuance by an issuer of common stock (or securities convertible into, or exercisable for, common stock) when the issuance or potential issuance of additional shares may result in a change of control of the issuer.
Tools for this story
Each opens in a new tab, filled in for Quantum Cyber N.V.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
